A Phase 3 interventional study of pseudoephedrine hydrochloride 30 mg tablets and Placebo tablets in Nasal Congestion Associated With the Common Cold, sponsored by Perrigo Company. Completed at 11 sites in United States. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2016-04-22.
Sponsored by Perrigo Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Common Cold with a site in United States — 7 open to participants now, 8 under way, none of them phase 3. Common Cold · United States.
Among the 47 studies in Common Cold with a site in United States, this one is the 8th largest by enrollment of the 40 interventional ones that give a count, is one of 5 that started in 2012, is one of 7 in phase 3, and was the 26th registered.
219 studies on the registry are indexed under Common Cold; 23 are open to participants now.
Browse Common Cold studies →7 of the 47 studies in Common Cold with a site in United States are open now. Recruiting first, the newest first:
University of Pittsburgh · Sites in United States
Ages 6 mo–24 mo
Colorado State University · Sites in United States
Ages 18–40 · Healthy volunteers
Quantec Ltd · Sites in United States
Ages 60+ · Healthy volunteers
Center For Interventional Pain and Spine · Sites in United States
Ages 18+ · Healthy volunteers
Indiana University · Sites in United States
Ages 18–40 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 15 Common Cold studies recruiting now, 4 (27%) set no upper age limit and 10 (67%) stop at 75 or younger; 5 take children under 18; 7 take healthy volunteers.
This study: 6 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 5 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 565 is above the median of 150 across 184 interventional studies indexed under Common Cold.
Median enrollment 228 across the 40 interventional studies, 121 across the 6 observational. Of the 37 that completed or were terminated, 14 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 47 have an industry lead sponsor. The 10 most frequent:
Perrigo Company is the lead sponsor of 7 studies on the registry; none are open to participants now.
Perrigo Company has 1 study filed under Common Cold — fewer than ten, so there is no comparison to draw.
3 of the studies in Common Cold with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05822141Indiana UniversityOmega-3 Fatty Acids as Regulators of Brown Adipose Tissue During Cold Exposure | 2026-12 |
| NCT07297823Colorado State UniversitySex Differences in Cold-Induced Changes in Maximal Fat Oxidation | 2026-12-31 |
| NCT07706595University of California, San DiegoA Randomized Controlled Trial Comparing Posterior Nasal Nerve Ablation Procedures for Chronic Rhinitis | 2027-08-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 47 studies in Common Cold with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to confirm the effectiveness of single-ingredient pseudoephedrine in children for the temporary relief of nasal congestion due to the common cold, an indication described under 21 CFR 341.80(b)(1).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Test product
Drug: pseudoephedrine hydrochloride 30 mg tablets
Placebo
Drug: Placebo tablets
Nasal Congestion Severity (NCSi) (instantaneous) scores
Weighted sum of change from baseline in Nasal Congestion Severity (NCSi) (instantaneous) scores over the first eight hours of treatment on Day 1
Time frame: 1 Day
change from baseline in NCSi scores from 0 to 4 hours
Sum of change from baseline in NCSi scores from 0 to 4 hours after the first dose on Day 1
Time frame: Day 1
change from baseline in NCSi scores from 6, 7, and 8 hours
Weighted sum of change from baseline in NCSi scores from 6, 7, and 8 hours after the first dose on Day 1
Time frame: Day 1
Nasal Congestion Relief (NCR) reflective scores at 4 hours and 8 hours
Sum of Nasal Congestion Relief (NCR) reflective scores at 4 hours and 8 hours on Day 1
Time frame: Day 1
NCSi score at each time point from 0 to 8 hours
NCSi score at each time point from 0 to 8 hours after the first dose on Day 1
Time frame: Day 1
NCSr (reflective) scores at 6 hours and 12 hours
Sum of NCSr (reflective) scores at 6 hours and 12 hours on Day 2
Time frame: Day 2
NCSr scores at 6 and 12 hours
NCSr scores at 6 and 12 hours on Day 2
Time frame: Day 2
change from baseline in the Nasal Symptom and Function (NSF) composite score of NCSi
Weighted sum of change from baseline in the Nasal Symptom and Function (NSF) composite score of NCSi, nasal breathing, and nasal clearing over the first eight hours of treatment on Day 1
Time frame: Day 1
Sum of change from baseline in NSF composite score from 0 to 4 hours
Sum of change from baseline in NSF composite score from 0 to 4 hours after the first dose on Day 1
Time frame: Day 1
Weighted sum of change from baseline in NSF composite score from 6, 7, and 8 hours
Weighted sum of change from baseline in NSF composite score from 6, 7, and 8 hours after the first dose on Day 1
Time frame: Day 1
morning sleep score on Days 2 through 7
Change from baseline in morning sleep score on Days 2 through 7
Time frame: Day 7
NSF composite score on Days 2 through 7
Change from baseline in NSF composite score on Days 2 through 7
Time frame: Day 7
NSF + S (sleep) composite score on Days 2 through 7
Change from baseline in the NSF + S (sleep) composite score on Days 2 through 7
Time frame: Day 7
The record gives a start of Nov 2012, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pseudoephedrine
Perrigo Company